Bausch Health Companies Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.3B | $9.6B | $8.8B | $8.1B | $8.4B |
| Selling, general & administrative | $3.4B | $3.3B | $2.9B | $2.6B | $2.6B |
| Research and development | $629.0M | $616.0M | $604.0M | $529.0M | $465.0M |
| Operating income | $1.8B | $1.5B | $963.0M | $454.0M | $450.0M |
| Interest expense | — | — | — | — | $1.4B |
| Pretax income | $367.0M | $167.0M | -$390.0M | -$129.0M | -$1.0B |
| Income tax expense | $247.0M | $239.0M | $221.0M | $83.0M | -$87.0M |
| Net income | $157.0M | -$46.0M | -$592.0M | -$225.0M | -$948.0M |
| Balance Sheet | |||||
| Cash and equivalents | $1.3B | $1.2B | $947.0M | $564.0M | $582.0M |
| Current assets | $6.2B | $5.8B | $5.6B | $4.2B | $5.6B |
| Total assets | $26.4B | $26.5B | $27.4B | $25.7B | $29.2B |
| Current liabilities | $4.2B | $6.8B | $4.3B | $3.9B | $5.2B |
| Total liabilities | $26.0B | $26.8B | $27.4B | $25.4B | $29.2B |
| Total debt | $20.2B | $20.5B | $21.0B | $19.1B | $22.9B |
| Stockholders' equity | -$554.0M | -$1.3B | -$1.0B | -$692.0M | -$106.0M |
| Cash Flow Statement | |||||
| Cash from operations | $1.4B | $1.6B | $1.0B | -$728.0M | $1.4B |
| Depreciation and amortization | $207.0M | $190.0M | $187.0M | $179.0M | $177.0M |
| Stock-based compensation | $216.0M | $150.0M | $132.0M | $126.0M | $128.0M |
| Capital expenditure | $397.0M | $337.0M | $215.0M | $218.0M | $269.0M |
| Free cash flow | $1.0B | $1.3B | $817.0M | -$946.0M | $1.2B |
| Impairments | $8.0M | $29.0M | $54.0M | $15.0M | $234.0M |
Shares outstanding 373.5M
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.